Case 2: Antiretroviral Regimens for Initial Therapy - Antiretroviral Rx

Case-Based Modules
Initial Evaluation
Dermatologic Manifestations
Oral Manifestations
OIs: Prophylaxis
OIs: Treatment
Antiretroviral Rx
Antiretroviral Rx: Resistance
Antiretroviral Rx: Adverse Effects
Drug-Drug Interactions
Postexposure Prophylaxis
Perinatal Transmission
Special Populations
Prevention for Positives
Challenging Unknowns
Interactive Tutorials
This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.

Home
About This Site
Free CME
AETC NRC
Resources
Feedback
Site Map
Authors

Question | Discussion | References | CME Credit

Case 2: Antiretroviral Regimens

You answered:

	Tenofovir-emtricitabine (Truvada) plus ritonavir (Norvir) plus darunavir (Prezista) is considered a preferred regimen.

This answer is correct. This regimen of tenofovir-emtricitabine plus ritonavir plus darunavir is considered a preferred regimen based on data that have shown excellent virologic responses and low frequency of side effects with this regimen.

[Back to Case 2 Question | Proceed to Case 2 Discussion]